Mycophenolic acid DR 360 MG TB 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FM3TZ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,028
Award facts
- Contract value 100% obligated
- $1,027.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,027.72 to AmerisourceBergen Drug Corp for the supply of Mycophenolic Acid delayed-release 360 milligram tablets (120-count bottles). The contract is a firm fixed-price delivery order with an ultimate completion date of February 5, 2026, and was awarded on February 4, 2026, with no set-aside designation. Performance will occur at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is executed under the parent company Cencora, Inc.'s existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for pharmaceutical and medical supply procurement to support military healthcare programs globally.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor in the federal medical procurement supply chain, supplying an extensive portfolio of medications and medical commodities including specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. The company competes on a full and open basis for federal contracts without set-aside protections. Mycophenolic acid is an immunosuppressant medication commonly used in transplant and autoimmune disease management within military treatment facilities and Veterans Health Administration programs, reflecting the strategic medical supply needs supported through the DLA's comprehensive pharmaceutical prime vendor program.
Quick answers
Who was awarded contract SPE2DR26FM3TZ?
SPE2DR26FM3TZ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FM3TZ worth?
The government has obligated $1,028 on SPE2DR26FM3TZ.
Is contract SPE2DR26FM3TZ an order under another contract?
Yes. SPE2DR26FM3TZ is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM3TZ competed?
The extent of competition for SPE2DR26FM3TZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award